[Sensitivity of Plasmodium falciparum to quinolines and therapeutic strategies: comparison of the situation in Africa and Madagascar between 1983 and 1986].
One thousand and twenty six P. falciparum strains isolated from cases imported in France and field surveys in four regions of Africa and Madagascar were studied in vitro against chloroquine, monodesethylamodiaquine, quinine and mefloquine, 917 in vivo tests were performed during field studies with chloroquine (10 and 25 mg/kg) and amodiaquine (10, 25, 35 mg/kg). In Madagascar, the chemoresistance remained low and stable during the study period, concerning mostly chloroquine (11% in vitro and in vivo) without obvious geographical variation. 25 mg/kg chloroquine or amodiaquine were satisfactory as respectively first and second line therapeutic regimen. In Central Africa, chemoresistance emerged with an epidemic profile and increased dramatically in disseminated urban focus. High level and prevalence of chloroquine resistance and multiresistance were observed few months after the index cases in these foci. In South West Cameroon, amodiaquine remained efficient as curative treatment but only at a dose of 35 mg/kg/5 days. Decrease of in vitro sensitivity and in vivo efficacy of quinine is a matter of concern. Given the heterogeneous and evolutive situation of drug resistance, the need for epidemiological surveillance and monitoring of P. falciparum drug sensitivity in Africa is obvious to adjust therapeutic regimen.
Le Bras
J
J
Centre National de Référence pour la Chimiosensibilité du Paludisme, Hôpital Claude-Bernard, Paris.
Simon
F
F
Ramanamirija
J A
JA
Calmel
M B
MB
Hatin
I
I
Deloron
P
P
Porte
J
J
Marchais
H
H
Clausse
J L
JL
Biaud
J M
JM
D000655:Amodiaquine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000810:Angola; D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use*; D002050:Burkina Faso; D002163:Cameroon; D002738:Chloroquine / Q000627:therapeutic use; D004351:Drug Resistance; D006801:Humans; D008270:Madagascar; D008288:Malaria / Q000188:drug therapy / Q000469:parasitology*; D015767:Mefloquine; D010963:Plasmodium falciparum / Q000187:drug effects*; D011803:Quinine / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use*
D000962:Antimalarials; D011804:Quinolines; D000655:Amodiaquine; C047386:desethylamodiaquine; D002738:Chloroquine; D011803:Quinine; D015767:Mefloquine
Sensibilité de Plasmodium falciparum aux quinoléines et stratégies thérapeutiques: comparaison de la situation en Afrique et à Madagascar entre 1983 et 1986.